Exciting Developments from GENFIT at AASLD 2025
GENFIT, a dedicated biopharmaceutical company, recently announced its significant involvement at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The gathering, which focuses on advancing liver disease research, is set to take place in November.
Deep Dive into ACLF Research
During this notable event, GENFIT will introduce new findings from its research into Acute on-Chronic Liver Failure (ACLF). The company aims to underscore the promising data surrounding its diverse pipeline of therapies, highlighting the lead program, G1090N, which is a reformulation of nitazoxanide.
G1090N – A Key Player
Featured prominently at the event, G1090N will have a dedicated poster session that describes its efficacy in combating systemic inflammation and enhancing organ function in models of ACLF. This cutting-edge research is essential as it promises solutions for patients facing severe liver complications.
SRT-015 and CLM-022 Insights
Another exciting study revolves around SRT-015, an ASK1 inhibitor shown to reduce systemic inflammation while boosting immune responses in preclinical models related to ACLF. Additionally, the efficacy of CLM-022, an NLRP3 inflammasome inhibitor, will be showcased, further expanding the therapeutic landscape for liver diseases.
New Insights on Iqirvo®
Partnering company, Ipsen, will also present crucial data about Iqirvo® (elafibranor), which addresses cholestatic liver diseases such as Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). The data is anticipated to highlight Iqirvo®'s potential to alleviate symptoms and manage disease progression effectively.
Exploring Real-World Evidence
Alongside posters on therapeutic advancements, GENFIT will also delve into real-world evidence regarding the management of ACLF. Featured research will include characterizations of patient experiences and care strategies used in hospitals, providing critical insights into the disease from a practical perspective.
Collaborative Efforts and Future Directions
These presentations reaffirm GENFIT's commitment to pioneering research in the field of liver diseases and the innovative approaches being taken to improve patient outcomes. With a portfolio focused on addressing significant unmet medical needs, GENFIT is at the forefront of transforming treatment methodologies for liver complications.
Looking Ahead: Events and Opportunities
GENFIT is organizing significant events during AASLD 2025, including discussions on ACLF and a patient advocacy council. These initiatives will enhance collaboration within the medical community to foster better understanding and management of liver diseases.
About GENFIT
GENFIT is a biopharmaceutical company committed to advancing therapies for patients suffering from rare liver diseases. With over two decades of experience in research and development, GENFIT continuously innovates to address the unmet needs of patients with ACLF and related conditions.
Frequently Asked Questions
What significant findings will GENFIT present at AASLD 2025?
GENFIT will share new data on its ACLF pipeline, including insights into G1090N and Iqirvo®.
What is the focus of the presentations regarding G1090N?
G1090N aims to show its efficacy in reducing systemic inflammation and enhancing organ function in ACLF models.
Who is presenting data on Iqirvo®?
Partner Ipsen will present key findings about Iqirvo® that showcase its efficacy in treating cholestatic liver diseases.
Are there any patient-focused events planned?
Yes, GENFIT is organizing a patient advocacy council and discussions focused on ACLF during the event.
What is GENFIT's commitment to liver disease research?
GENFIT is dedicated to innovating therapies for rare liver diseases, emphasizing patient needs and advancing medical research.
